Published in Virology on May 01, 1978
Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science (1992) 4.49
Cytomegalovirus infectivity: analysis of the phenomenon of centrifugal enhancement of infectivity. Virology (1976) 3.44
Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell (1985) 3.36
Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J Virol (1992) 2.99
Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol (1991) 2.79
Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J Gen Virol (1971) 2.59
Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology (1967) 2.41
Some properties of the genome of murine cytomegalovirus (MCV). Virology (1973) 2.40
Mechanisms of neutralization of animal viruses. J Gen Virol (1984) 2.16
The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Arch Virol (1979) 1.88
Review article initial stages in infection with animal viruses. J Gen Virol (1982) 1.87
Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83
Smad proteins act in combination with synergistic and antagonistic regulators to target Dpp responses to the Drosophila mesoderm. Genes Dev (1998) 1.77
An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology (1969) 1.65
Identification of a neutralization-specific antigen of a calf rotavirus. J Gen Virol (1982) 1.64
New virus-specific antigens in cells infected with influenza virus. Virology (1969) 1.48
Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol (1969) 1.47
Clinical significance of virulence-related assay of Yersinia species. J Clin Microbiol (1987) 1.46
Defective interfering viruses and their potential as antiviral agents. Rev Med Virol (2010) 1.44
Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37
Neutralization of animal virus infectivity by antibody. Arch Virol (2007) 1.34
In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene (1990) 1.32
Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med (1985) 1.29
Electrophoretic separation of influenza virus ribonucleoproteins. J Gen Virol (1981) 1.27
Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol (1994) 1.26
Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol (1990) 1.24
A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology (1997) 1.24
Biophysical studies of a rhinovirus. Extraction and assay of infectious ribonucleic acid. Nature (1966) 1.19
Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology (1975) 1.19
Immunosuppressive effect of murine cytomegalovirus. Infect Immun (1980) 1.13
Antiviral and antimicrobial activities of Colombian medicinal plants. J Ethnopharmacol (2001) 1.12
Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect (1991) 1.12
Polyadenylic acid sequences in rhinovirus RNA species from infected human diploid cells. J Virol (1975) 1.11
Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus. J Gen Virol (1978) 1.09
The RNAs of defective-interfering influenza virus. Virology (1978) 1.09
Multiple interactions between murine cytomegalovirus and lymphoid cells in vitro. J Gen Virol (1978) 1.08
An analysis of the polyoma virus DNA-RNA hybridization reaction in vitro. Eur J Biochem (1969) 1.08
Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol (1994) 1.08
Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J Gen Virol (1982) 1.07
Regulation of murine cytomegalovirus gene expression. I. Transcription during productive infection. J Virol (1978) 1.07
Defective segment 1 RNAs that interfere with production of infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol (2002) 1.06
Proteins of murine cytomegalovirus: identification of structural and nonstructural antigens in infected cells. Virology (1978) 1.06
A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol (2001) 1.06
Development of DNA probes for Candida albicans. Diagn Microbiol Infect Dis (1988) 1.05
Thymidine kinase activity in mouse 3T3 cells infected by murine cytomegalovirus (MCV). Virology (1977) 1.05
Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol (1997) 1.05
Interaction of murine cytomegalovirus with separated populations of spleen cells. Infect Immun (1979) 1.05
Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol (2001) 1.04
Approximately 150 nucleotides from the 5' end of an influenza A segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology (2000) 1.03
Identification and characterization of a murine cytomegalovirus gene with homology to the UL25 open reading frame of human cytomegalovirus. Virology (1994) 1.03
Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates. J Gen Virol (1970) 1.02
Effect of bacteriophage R17 infection on host-directed synthesis of ribosomal ribonucleates. J Virol (1967) 1.01
The enumeration of viral genomes in murine cytomegalovirus-infected cells. Virology (1977) 1.01
Phosphorylation of influenza virus nucleoprotein in vivo. J Gen Virol (1981) 1.01
'Integration' of polyoma virus DNA into mammalian genomes. Biochem Biophys Res Commun (1972) 1.01
Failure of an influenza virus to initiate infection in enucleate BHK cells. J Virol (1974) 1.00
Functional changes in murine macrophages infected with cytomegalovirus relate to H-2-determined sensitivity to infection. J Virol (1987) 0.99
Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol (1990) 0.98
Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses (1995) 0.98
Early events in influenza virus multiplication. II. Penetration of virus into cells at 4 degrees. Virology (1978) 0.97
Murine cytomegalovirus infection in the spleen and its relationship to immunosuppression. Infect Immun (1981) 0.97
Fowl plaque virus replication in mammalian cell-avian erythrocyte heterokaryons: studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication. Virology (1974) 0.96
Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines. Gynecol Oncol (1993) 0.96
Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus. J Gen Virol (1989) 0.95
Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol (1985) 0.95
Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. J Infect Dis (1997) 0.95
Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol (1996) 0.94
Replication of rhinovirus RNA. J Gen Virol (1973) 0.94
Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect (1997) 0.94
Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. Virology (1980) 0.94
Properties of the multicapsid virions of murine cytomegalovirus. Virology (1976) 0.94
Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine (2006) 0.94
Common sequence elements in structurally unrelated genomes of defective interfering Semliki Forest virus. Virology (1994) 0.93
Location of influenza virus M, NP and NS1 proteins in microinjected cells. J Gen Virol (1985) 0.93
Structural and functional heterogeneity of the murine cytomegalovirus genome. Virology (1974) 0.93
Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res (2006) 0.93
High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol (1997) 0.93
Kinetics of synthesis of influenza virus ribonucleoprotein structures. J Gen Virol (1982) 0.92
Cell cycle dependency of murine cytomegalovirus replication in synchronized 3T3 cells. J Virol (1977) 0.92
Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol (1986) 0.91
Bactericidal and anti-inflammatory properties of a standardized Echinacea extract (Echinaforce): dual actions against respiratory bacteria. Phytomedicine (2009) 0.91
Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Experientia (1996) 0.91
Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology (1977) 0.90
Temporal control of transcription of influenza virus RNA. Virology (1975) 0.90
One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J Gen Virol (1988) 0.90
Vertical transmission of murine cytomegalovirus. J Gen Virol (1979) 0.89
Antiviral activities of Nepalese medicinal plants. J Ethnopharmacol (1996) 0.89
Ultrastructural study of lesions induced in rabbit cornea by Herpes Simplex virus types 1 and 2. J Infect Dis (1976) 0.89
The antiviral action of lignans. Planta Med (1989) 0.89
Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine (1999) 0.89
Antiviral activities of medicinal plants of southern Nepal. J Ethnopharmacol (1996) 0.89